Xingya Li

5.5k total citations · 1 hit paper
77 papers, 1.1k citations indexed

About

Xingya Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xingya Li has authored 77 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Xingya Li's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (24 papers) and Colorectal Cancer Treatments and Studies (17 papers). Xingya Li is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (24 papers) and Colorectal Cancer Treatments and Studies (17 papers). Xingya Li collaborates with scholars based in China, United States and Türkiye. Xingya Li's co-authors include Siyuan Huang, Ningning Yan, James O’Rourke, Huixian Zhang, Robert E. Cone, Jian Fang, Huijie Fan, Jing Yuan, Yanqiu Zhao and Yun Fan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Xingya Li

73 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

2024 56 citations Ying Cheng, Yanqiu Zhao et al. Journal of Thoracic Oncology profile →

Peers

Xingya Li

ONCOL

PRM

IMMUN

Etienne Giroux‐Leprieur France

Xinmin Yu China

Zhanhong Xie China

Jinpeng Shi China

Danilo Rocco Italy

Shugeng Gao China

Nahomi Tokudome Japan

Rocco Sacco Italy

Satoru Kitazono Japan

Michele Prisciandaro Italy

Etienne Giroux‐Leprieur France

Xingya Li

1.0k ×1.7

ONCOL

706 ×1.3

PRM

492 ×1.4

252 ×1.0

194 ×1.6

IMMUN

Citations per year, relative to Xingya Li Xingya Li (= 1×) peers Etienne Giroux‐Leprieur

Countries citing papers authored by Xingya Li

Since Specialization

Citations

This map shows the geographic impact of Xingya Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingya Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingya Li more than expected).

Fields of papers citing papers by Xingya Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingya Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingya Li. The network helps show where Xingya Li may publish in the future.

Co-authorship network of co-authors of Xingya Li

This figure shows the co-authorship network connecting the top 25 collaborators of Xingya Li. A scholar is included among the top collaborators of Xingya Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingya Li. Xingya Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248. 5 indexed citations

Huang, Siyuan, Ningning Yan, Qianqian Guo, et al.. (2024). Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment. Frontiers in Oncology. 14. 1331387–1331387. 1 indexed citations

Yan, Ningning, Huixian Zhang, Sanxing Guo, et al.. (2024). Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data. Frontiers in Oncology. 14. 1353491–1353491. 1 indexed citations

Shi, Yuankai, Xingsheng Hu, Xingya Li, et al.. (2024). Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study. Journal of Thoracic Oncology. 19(6). 898–911.

Xiong, Anwen, Wei Li, Xingya Li, et al.. (2023). Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. European Journal of Cancer. 190. 112936–112936. 17 indexed citations

Li, Linlin, et al.. (2023). Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review. Frontiers in Pharmacology. 14. 1257592–1257592. 2 indexed citations

Mao, Shiqi, Shuo Yang, Xinyu Liu, et al.. (2023). Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials. Experimental Hematology and Oncology. 12(1). 53–53. 5 indexed citations

Shi, Yuankai, Jianying Zhou, Yanqiu Zhao, et al.. (2023). Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC Medicine. 21(1). 11–11. 8 indexed citations

Ma, Ke, Qianqian Guo, & Xingya Li. (2023). Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study. BMC Pulmonary Medicine. 23(1). 175–175. 7 indexed citations

10.

Yan, Ningning, Siyuan Huang, Lin Li, et al.. (2022). Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report. Frontiers in Pharmacology. 13. 898623–898623. 3 indexed citations

11.

Dong, Xiaorong, Xingya Li, Jianhua Chen, et al.. (2022). Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors. JTO Clinical and Research Reports. 4(2). 100449–100449. 4 indexed citations

12.

Lin, Lin, Hongming Pan, Xingya Li, et al.. (2022). A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung Cancer. 166. 98–106. 3 indexed citations

13.

Li, Mingjun, et al.. (2021). Correction to: Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6. Cancer Cell International. 21(1). 289–289.

14.

Yang, Jin‐Ji, Cheng Huang, Yun Fan, et al.. (2021). Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. Cancer Immunology Immunotherapy. 71(6). 1393–1402. 15 indexed citations

15.

Li, Mingjun, et al.. (2020). Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6. Cancer Cell International. 20(1). 574–574. 25 indexed citations

16.

Guo, Sanxing, Yonggang Shi, Shuo Lu, et al.. (2020). The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis. Journal of Cancer. 11(22). 6653–6662. 1 indexed citations

17.

Zhang, Pan, et al.. (2015). Askin's tumor: 11 cases and a review of the literature. Oncology Letters. 11(1). 253–256. 10 indexed citations

18.

Zhang, Yanfang, et al.. (2009). The expression of tumor-infiltrating lymphocytes and its relationship with prognosis of esophageal carcinoma.. Tumori. 29(4). 363–366. 2 indexed citations

19.

Cone, Robert E., et al.. (2006). The suppression of delayed‐type hypersensitivity by CD8⁺ regulatory T cells requires interferon‐γ. Immunology. 120(1). 112–119. 30 indexed citations

20.

Li, Xingya, et al.. (2004). Thymocytes induced by antigen injection into the anterior chamber activate splenic CD8⁺ suppressor cells and enhance the antigen‐induced production of immunoglobulin G1 antibodies. Immunology. 113(1). 44–56. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact